Search

Your search keyword '"Valsecchi, Diletta"' showing total 18 results
Start Over Author "Valsecchi, Diletta"
18 results on '"Valsecchi, Diletta"'

5. The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy

Author

Breccia, Massimo, primary, Chiodi, Francesca, additional, Nardozza, Aurelio Pio, additional, Valsecchi, Diletta, additional, Perrone, Valentina, additional, Sangiorgi, Diego, additional, Giacomini, Elisa, additional, Rendace, Maria Chiara, additional, Coco, Paola, additional, Premoli, Eleonora, additional, and Degli Esposti, Luca, additional

Published
2022
Full Text
View/download PDF

6. Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy

Author

Palladino, Simona, Perrone, Valentina, Giacomini, Elisa, Sangiorgi, Diego, Premoli, Eleonora, Valsecchi, Diletta, Degli Esposti, Luca, and Suter, Matteo Basilio

Abstract

This real-world analysis evaluated drug utilization focusing on wastage and healthcare costs for treatment of patients with advanced breast cancer (aBC) hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) in Italy. A retrospective analysis was conducted on administrative data covering about 13.3 million health-assisted individuals. Across January/2017–June/2021, all patients with HR+/HER2-aBC were identified by ≥ 1 prescription for cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i). Cost analysis was performed and updated referring to the prices of November 2021. Overall, 3,647 HR+/HER2-aBC patients were included (2,627 palbociclib treated, 729 ribociclib treated, and 291 abemaciclib treated). After 12 months of follow-up, 35% of palbociclib patients had a dose reduction (on average 8.9 wasted pills/patient), 44.7% of abemaciclib patients had a dose reduction (on average 6.7 wasted pills/patient), 22.1% of ribociclib patients had a dose reduction (no wasted pills). Therapy wastage added up to 528,716€ for palbociclib-treated patients (524€/patient) and 5,738€ in abemaciclib-treated patients (151€/patient). No wastage was attributed to ribociclib. Dose reduction was associated with drug wastage in palbociclib and abemaciclib-treated patients, but not in ribociclib-treated ones. These findings might be helpful to policy decision-makers who, for healthcare strategies implementation, among several variables should consider the possible restraining of drug wastage.

Published
2023
Full Text
View/download PDF

7. Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Author

Stagno, Fabio, primary, Abruzzese, Elisabetta, additional, Iurlo, Alessandra, additional, Pane, Fabrizio, additional, Attolico, Imma, additional, Sportoletti, Paolo, additional, Pregno, Patrizia, additional, Galimberti, Sara, additional, Scappini, Barbara, additional, Miglino, Maurizio, additional, Siragusa, Sergio, additional, Capodanno, Isabella, additional, Valsecchi, Diletta, additional, Nardozza, Aurelio Pio, additional, Coco, Paola, additional, Rosti, Gianantonio, additional, Saglio, Giuseppe, additional, and Breccia, Massimo, additional

Published
2022
Full Text
View/download PDF

8. A Phase II, Single-Arm Study of De-Escalation and Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line Therapy Followed By a Second Attempt after Nilotinib and Asciminib Combination: Dante Study

Author

Rosti, Gianantonio, primary, Saglio, Giuseppe, additional, Stagno, Fabio, additional, Valsecchi, Diletta, additional, Nardozza, Aurelio Pio, additional, Coco, Paola, additional, Breccia, Massimo, additional, and Iurlo, Alessandra, additional

Published
2022
Full Text
View/download PDF

9. Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Author

Papayannidis, Cristina, primary, Mannelli, Francesco, additional, Crosera, Lara, additional, Parente, Roberta, additional, Romano, Alessandra, additional, Rondoni, Michela, additional, Elena, Chiara, additional, Criscuolo, Marianna, additional, Di Renzo, Nicola, additional, Giona, Fiorina, additional, Pane, Fabrizio, additional, Cilloni, Daniela, additional, Elli, Elena Maria, additional, Miglino, Maurizio, additional, Mazza, Patrizio, additional, Malato, Alessandra, additional, Pochintesta, Lara, additional, Bini, Roberta, additional, Valsecchi, Diletta, additional, and Grifoni, Federica Irene, additional

Published
2022
Full Text
View/download PDF

10. Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy

Author

Breccia, Massimo, primary, Chiodi, Francesca, additional, Nardozza, Aurelio Pio, additional, Valsecchi, Diletta, additional, Perrone, Valentina, additional, Sangiorgi, Diego, additional, Giacomini, Elisa, additional, Rendace, Maria Chiara, additional, Coco, Paola, additional, Premoli, Eleonora, additional, and Degli Esposti, Luca, additional

Published
2022
Full Text
View/download PDF

11. Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy.

Author

De Franceschi, Lucia, Castiglioni, Chiara, Condorelli, Claudia, Valsecchi, Diletta, Premoli, Eleonora, Fiocchi, Carina, Perrone, Valentina, Esposti, Luca Degli, and Forni, Gian Luca

Subjects
SICKLE cell anemia, ECONOMIC impact of disease, DIRECT costing, HOSPITAL emergency services
Abstract

A real-world analysis was conducted in Italy among sickle cell disease (SCD) patients to evaluate the epidemiology of SCD, describe patients' characteristics and the therapeutic and economic burden. A retrospective analysis of administrative databases of various Italian entities was carried out. All patients with ≥1 hospitalization with SCD diagnosis were included from 01/2010-12/2017 (up to 12/2018 for epidemiologic analysis). The index date corresponded to the first SCD diagnosis. In 2018, SCD incidence rate was 0.93/100,000, the prevalence was estimated at 13.1/100,000. Overall, 1816 patients were included. During the 1st year of follow-up, 50.7% of patients had one all-cause hospitalization, 27.8% had 2, 10.4% had 3, and 11.1% had ≥4. Over follow-up, 6.1–7.2% of patients were treated with SCD-specific, 58.4–69.4% with SCD-related, 60.7–71.3% with SCD-complications-related drugs. Mean annual number per patient of overall treatments was 14.9 ± 13.9, hospitalizations 1.1 ± 1.1, and out-patient services 5.3 ± 7.6. The total mean direct cost per patient was EUR 7918/year (EUR 2201 drugs, EUR 3320 hospitalizations, and EUR 2397 out-patient services). The results from this real-world analysis showed a high disease burden for SCD patients with multiple hospitalizations during the follow-up. High healthcare resource utilization and costs were associated with patient' management and were most likely underestimated since indirect costs and Emergency Room admissions were not included. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Author

Iurlo, Alessandra, Breccia, Massimo, Stagno, Fabio, Abruzzese, Elisabetta, Pane, Fabrizio, Attolico, Immacolata, Sportoletti, Paolo, Cerrano, Marco, Galimberti, Sara, Scappini, Barbara, Miglino, Maurizio, Siragusa, Sergio, Capodanno, Isabella, Valsecchi, Diletta, Nardozza, Aurelio Pio, Misto, Alessandra, Coco, Paola, Saglio, Giuseppe, and Rosti, Gianantonio

Published
2023
Full Text
View/download PDF

15. Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)

Author

De Laurentiis, Michelino, primary, Malorni, Luca, additional, Bianchini, Giampaolo, additional, Caputo, Roberta, additional, Giuliano, Mario, additional, Zambelli, Alberto, additional, Puglisi, Fabio, additional, Mastro, Lucia Del, additional, Colleoni, Marco, additional, Montemurro, Filippo, additional, Bianchi, Giulia, additional, Paris, Ida, additional, Allegrini, Giacomo, additional, Amaducci, Laura, additional, Cazzaniga, Marina Elena, additional, Orditura, Michele, additional, Zamagni, Claudio, additional, Adamo, Vincenzo, additional, Guarnieri, Valentina, additional, Battelli, Nicola, additional, Valerio, Maria Rosaria, additional, Cinieri, Saverio, additional, Bianchetti, Sara, additional, Grasso, Donatella, additional, Castelletti, Daniela, additional, Valsecchi, Diletta, additional, Cotroneo, Ettore, additional, and Arpino, Grazia, additional

Published
2020
Full Text
View/download PDF

16. Adherence to Ruxolitinib, an Oral JAK1/2 Inhibitor, in Patients With Myelofibrosis: Interim Analysis From an Italian, Prospective Cohort Study (ROMEI)

Author

Guglielmelli, Paola, primary, Palandri, Francesca, additional, Selleri, Carmine, additional, Cilloni, Daniela, additional, Mendicino, Francesco, additional, Mazza, Patrizio, additional, Pastore, Domenico, additional, Palumbo, Giuseppe A., additional, Santoro, Marco, additional, Pavone, Vincenzo, additional, Impera, Stefana, additional, Morelli, Mara, additional, Coco, Paola, additional, Valsecchi, Diletta, additional, Passamonti, Francesco, additional, Breccia, Massimo, additional, and Group, ROMEI Study, additional

Published
2020
Full Text
View/download PDF

17. Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).

Author

Guglielmelli, Paola, Palandri, Francesca, Selleri, Carmine, Cilloni, Daniela, Mendicino, Francesco, Mazza, Patrizio, Pastore, Domenico, Palumbo, Giuseppe A., Santoro, Marco, Pavone, Vincenzo, Impera, Stefana, Morelli, Mara, Coco, Paola, Valsecchi, Diletta, Passamonti, Francesco, and Breccia, Massimo

Subjects
RUXOLITINIB, PATIENT compliance, MYELOFIBROSIS, LONGITUDINAL method, COHORT analysis
Abstract

ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8). Here, we present MMAS-8 results at week 24. Overall, 101 of 188 evaluable patients completed the questionnaire at every visit (full completers). Mean (±standard deviation) total MMAS-8 scores remained stable from week 4 to week 24 in the overall population (7.54 ± 0.77 and 7.67 ± 0.70, respectively) and full completers (7.53 ± 0.79 and 7.67 ± 0.73, respectively). Rates of low (MMAS-8 ˂6) or medium (MMAS-8 ≥ 6 to ˂8) adherence were 25–40% and 26–36%, respectively. Fifty-five full completers (54%) reported ≥1 change in adherence category (improvement and/or worsening), most of which were associated with unintentional behavior. The data suggest that one-third of patients receiving ruxolitinib may be undertreated due to non-adherence, potentially undermining disease control, and indicate a need for better interventions addressing noncompliance to oral therapies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

18. Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy.

Author

De Franceschi L, Castiglioni C, Condorelli C, Valsecchi D, Premoli E, Fiocchi C, Perrone V, Esposti LD, Forni GL, and On Behalf Of The GREATalyS Study Group

Abstract

A real-world analysis was conducted in Italy among sickle cell disease (SCD) patients to evaluate the epidemiology of SCD, describe patients' characteristics and the therapeutic and economic burden. A retrospective analysis of administrative databases of various Italian entities was carried out. All patients with ≥1 hospitalization with SCD diagnosis were included from 01/2010-12/2017 (up to 12/2018 for epidemiologic analysis). The index date corresponded to the first SCD diagnosis. In 2018, SCD incidence rate was 0.93/100,000, the prevalence was estimated at 13.1/100,000. Overall, 1816 patients were included. During the 1st year of follow-up, 50.7% of patients had one all-cause hospitalization, 27.8% had 2, 10.4% had 3, and 11.1% had ≥4. Over follow-up, 6.1-7.2% of patients were treated with SCD-specific, 58.4-69.4% with SCD-related, 60.7-71.3% with SCD-complications-related drugs. Mean annual number per patient of overall treatments was 14.9 ± 13.9, hospitalizations 1.1 ± 1.1, and out-patient services 5.3 ± 7.6. The total mean direct cost per patient was EUR 7918/year (EUR 2201 drugs, EUR 3320 hospitalizations, and EUR 2397 out-patient services). The results from this real-world analysis showed a high disease burden for SCD patients with multiple hospitalizations during the follow-up. High healthcare resource utilization and costs were associated with patient' management and were most likely underestimated since indirect costs and Emergency Room admissions were not included.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results